Back to Search
MARVIN PEYTON, M.D.
M.D.
Psychiatry Physician
NPI: 1578644803IndividualAccepts Medicare
Education
UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE
Class of 2004
Research & Publications (20)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
PMID 19351834·Cancer Res·2009
8-other
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
PMID 19451690·J Clin Invest·2009
7-preclinical
SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function.
PMID 19262564·EMBO J·2009
7-preclinical
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
PMID 19238210·PLoS One·2009
8-other
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
PMID 19179890·J Thorac Oncol·2009
7-preclinical
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
PMID 19117057·Int J Cancer·2009
8-other
Implications of EGFR inhibition in ovarian cancer cell proliferation.
PMID 18423824·Gynecol Oncol·2008
8-other
Infective endocarditis of a papillary fibroelastoma on Chiari network of right atrium: a case report.
PMID 17928193·J Am Soc Echocardiogr·2008
5-case
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.
PMID 17996648·Cancer Cell·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2301 W I 44 SERVICE RD, SUITE 300
OKLAHOMA CITY, OK 73112 - Phone
- (405) 607-2233
Quick Facts
- NPI
- 1578644803
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 22
- Publications
- 20
Are you this provider?
Claim Your Profile